Abstract | PURPOSE OF REVIEW: RECENT FINDINGS: SUMMARY:
Tyrosine kinase inhibition as a potential strategy for the treatment of systemic sclerosis has been gaining more widespread interest based on preclinical data and open-label experiences. Large, multicenter, double-blind, randomized controlled trials are needed to assess the efficacy and safety of this approach in this complex disease.
|
Authors | Jessica K Gordon, Robert F Spiera |
Journal | Current opinion in rheumatology
(Curr Opin Rheumatol)
Vol. 22
Issue 6
Pg. 690-5
(Nov 2010)
ISSN: 1531-6963 [Electronic] United States |
PMID | 20827202
(Publication Type: Journal Article, Review)
|
Chemical References |
- Protein Kinase Inhibitors
- Protein-Tyrosine Kinases
|
Topics |
- Animals
- Disease Models, Animal
- Fibrosis
- Humans
- Mice
- Protein Kinase Inhibitors
(pharmacology, therapeutic use)
- Protein-Tyrosine Kinases
(antagonists & inhibitors, metabolism, physiology)
- Scleroderma, Systemic
(drug therapy, enzymology, pathology)
|